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Abstract
Background and Goals: Hepatitis A (HAV) and hepatitis B (HBV) vaccination in patients with chronic liver disease is an
accepted standard of care. We determined HAV and HBV vaccination rates in a tertiary care referral hepatology clinic and
the impact of electronic health record (EHR)-based reminders on adherence to vaccination guidelines.
Methods: We reviewed the records of 705 patients with chronic liver disease referred to our liver clinic in 2008 with at least
two follow-up visits during the subsequent year. Demographics, referral source, etiology, and hepatitis serology were
recorded. We determined whether eligible patients were offered vaccination and whether patients received vaccination.
Barriers to vaccination were determined by a follow-up telephone interview.
Results: HAV and HBV serologic testing prior to referral and at the liver clinic were performed in 14.5% and 17.7%; and
76.7% and 74% patients, respectively. Hepatologists recommended vaccination for HAV in 63% and for HBV in 59.7% of
eligible patients. Patient demographics or disease etiology did not influence recommendation rates. Significant variability
was observed in vaccination recommendation amongst individual providers (30–98.6%), which did not correlate with the
number of patients seen by each physician. Vaccination recommendation rates were not different for Medicare patients
with hepatitis C infection for whom a vaccination reminder was automatically generated by the EHR. Most patients who
failed to get vaccination after recommendation offered no specific reason for noncompliance; insurance was a barrier in a
minority.
Conclusions: Hepatitis vaccination rates were suboptimal even in an academic, sub-speciality setting, with wide-variability
in provider adherence to vaccination guidelines.
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Introduction
Hepatitis A and hepatitis B are amongst the most common
infectious diseases worldwide [1,2]. Superinfection with hepatitis A
virus (HAV) or hepatitis B virus (HBV) in patients with underlying
chronic liver disease is associated with a higher risk of morbidity
and mortality [3,4,5]. Both HAV and HBV infections are
preventable by highly effective and safe vaccines [6,7,8,9]. Experts
have recommended screening for susceptibility to HAV and HBV
infection and vaccination against them for all patients with chronic
liver disease [10,11]. The CDC and several professional societies
have also recommended vaccination against HAV and HBV for
susceptible patients with chronic liver disease. In 2008, Centers for
Medicare and Medicaid Services (CMS) proposed HAV and HBV
vaccination for eligible patients with chronic hepatitis C infection
(HCV) as a quality measure [12,13,14,15].
Prior studies have demonstrated shortcomings in adherence to
vaccination guidelines in specific subgroups of patients with
chronic liver disease in the United States and around the world. In
a study of patients with chronic hepatitis C infection in a Veterans
Administration Healthy System in California, an adherence rate of
71% for HAV and 70% for HBV and 62% for both vaccination
was found [16]. Similarly, in a large cohort of HCV patients from
the Department of Veterans Affairs quality measure of HAV and
HBV vaccination or documentation of immunity were met in just
57% and 45.5% patients, respectively [17]. A study of patients
with autoimmune hepatitis from Germany found vaccination rates
of just 11% for HBV and 13% for HAV [18].
Given the increased focus on preventive care and advent of pay
for performance models of health care delivery, it likely that
adherence to vaccination guideline will be emphasized as a quality
measure. Low adherence to vaccination guidelines in primary care
settings has been documented [19]. However, limited data are
available on whether specialists that care for chronic liver disease
patients perform better on these quality measures than community
physicians [19]. Furthermore, it is also unknown whether adoption
of electronic health records (EHR) and introduction of CMS-
mandated quality measures reporting has affected physician
practice patterns in terms of adhering to hepatitis vaccination
guidelines.
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Therefore, the objectives of this study were: (1) To evaluate
adherence to hepatitis vaccination guidelines in patients with
chronic liver disease at a tertiary care hepatology clinic, (2) to
identify barriers to vaccinations in patients with chronic liver
disease, and (3) to determine physician variability in adherence to
vaccination guidelines.
Methods
Study setting
This study was approved by the University of Pittsburgh
Medical Center (UPMC) Quality Improvement Committee and
the Institutional Review Board waived the need for written
informed consent from the participants. The study was conducted
at the Center for Liver Diseases (CLD) of the UPMC-Presbyterian
Hospital (PUH). PUH is an 800-bed, level 1, fully accredited
regional trauma center and the primary teaching hospital of the
University of Pittsburgh School of Medicine where residents and
fellows train in a wide variety of medical specialties and sub-
specialties. The CLD is the outpatient clinic for evaluation and
management of patients with liver diseases referred to PUH. The
CLD is staffed by 6–8 hepatologists, 3 advanced practice
providers, 6–8 nurses, and 8–10 nurse’s aides and medical
assistants and 100% of the clinic’s practice is focused on liver
diseases.
Study cohort
We reviewed medical records of all new patients (n = 820) who
were evaluated at the UPMC liver clinic in the year 2008 to
identify the study population for this study. Patients were eligible if
they had chronic liver disease that meets criteria for vaccination
for hepatitis A and B, and had a minimum of two follow-up visits
during the subsequent 12 months. Patients with chronic hepatitis
B (as suggested by positive Hepatitis B surface antigen (HBsAg)
were excluded. Therefore, the final study cohort consisted of 705
patients.
Data Collection
A detailed chart review (including paper records from referring
physicians) was performed for all patients who formed the final
study cohort to collect information on demographics, referral
source, etiology of chronic liver disease, presence of cirrhosis,
evidence of decompensation, primary CLD provider, whether
serological testing for HAV (hepatitis A antibody [total]) and HBV
(HBsAg, hepatitis B surface antibody [HBsAb], hepatitis B core
antibody [HBcAb]) was performed (prior to or at the CLD), results
of HAV and HBV serology, whether a patient received
vaccination prior to CLD referral, whether vaccination was
recommended in eligible patients at the CLD, and barriers to
vaccination in patients in whom vaccination was recommended at
the CLD but who did not get vaccinated. Patients who were
recommended but did not receive vaccination were contacted by
telephone by one of the investigators (KT) to determine the
reason(s). Patients that could not contacted to confirm their
vaccination status were categorized as having unknown vaccina-
tion status.
In 2008, CMS introduced HAV and HBV vaccination as a
PQRI measure for Medicare patients with chronic HCV infection.
This PQRI measure was incorporated in the CLD clinical
workflow in the form of an electronic reminder window that was
activated as soon as the provider chose chronic HCV as a
diagnosis for a Medicare patient. Providers were required to
complete the PQRI questionnaire before the electronic chart
could be closed for billing. To determine whether vaccination
recommendation rates differed based on Medicare status of the
patients, we electronically retrieved information on whether a
patient had Medicare insurance at any point during the year 2008.
Definition of eligibility for vaccination
For hepatitis A, patients who had a negative HAV antibody
were considered eligible for vaccination. For hepatitis B, patients
who were negative for HBs antigen, HBs antibody and HBc
antibody were considered eligible. Since there are no specific
guidelines for vaccination in patients with isolated HBc antibody,
we excluded these patients for evaluation of vaccination adher-
ence.
Statistical analysis
Descriptive analyses are presented as proportions for categorical
data, and as median and interquartile range (IQR) for continuous
data. Univariate analysis for categorical data was performed using
Table 1. Demographics, etiology and disease status of the
study population (N = 705).
Variable
Age (years) – median (IQR) 53 (44, 60)
Male gender – n (%) 373 (52.9)
Race – n (%)
White 604 (85.7)
Black 80 (11.3)
Other/Unknown 21 (3.0)
Referral Source – n (%)
Primary Care Physician 403 (57.2)
Gastroenterologist 116 (16.5)
Other Physicians 75 (10.6)
Unknown 111 (15.7)
Number of etiologies – n (%)
One 587 (83.3)
Two 111 (15.7)
More than two 7 (1.0)
Etiology – n (%)ˆ
Hepatitis C 347 (49.2)
Alcohol 122 (17.3)
NAFLD/NASH 199 (28.2)
PBC 33 (4.7)
PSC 29 (4.1)
Autoimmune Hepatitis 46 (6.5)
Hereditary Hemachromatosis 10 (1.4)
Hepatocellular Carcinoma 7 (1.0)
Other Liver tumors 4 (0.6)
Others 33 (4.7)
Cirrhosis – n (%) 276 (39.1)
Decompensated Cirrhosis – n (%)* 99 (35.9)
IQR – interquartile range.
^Total is more than 705 due to overlap of etiologies.
NAFLD – nonalcoholic fatty liver disease; NASH – nonalcoholic steatohepatitis;
PBC – Primary biliary cirrhosis; PSC – Primary sclerosing cholangitis.
*Proportion among patients with cirrhosis.
doi:10.1371/journal.pone.0071124.t001
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Figure 1. Flowcharts showing how often new patients with chronic liver disease were tested for, eligible for, and were
recommended hepatitis vaccination in the liver clinic. A) Hepatitis A vaccination. *Patients not eligible for HAV vaccination included those
with positive HAV antibody or who reported completion of the HAV vaccination series. B) HBV vaccination. *Patients not eligible for HBV vaccination
included those who had a positive HBs antibody and/or positive HBc antibody or who reported completion of the HBV vaccination series.
doi:10.1371/journal.pone.0071124.g001
Table 2. Number of new patients with chronic liver disease tested for Hepatitis A and B immunity before or at the liver clinic in the
year 2008.
Variable
Before Center for
Liver Diseases Visit N (%)
At Center for
Liver Diseases N (%)
Before or at Center for
Liver Diseases N (%)
Hepatitis A
Antibody tested 102 (14.5) 541 (76.7) 619 (87.8)
Antibody positive 24 (23.5) 166 (30.6) 183 (29.5)
Hepatitis B
HBs antigen tested 198 (28.1) 507 (71.9) 637 (90.4)
HBs antibody
Tested 125 (17.7) 522 (74) 596 (84.5)
Positive 32 (25.6) 154 (29.5) 176 (29.5)
HBc antibody
Tested 109 (15.5) 524 (74.3) 591 (83.8)
Positive 24 (22.0) 94 (17.9) 111 (18.8)
HAV vaccine received before patient seen at Center for Liver Diseases –47 (6.7).
HBV vaccine received before patient seen at Center for Liver Diseases –67 (9.5).
doi:10.1371/journal.pone.0071124.t002
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the chi-squared or Fisher’s exact test as appropriate and, for
continuous variables, using Mann-Whitney-U test. Data analysis
was performed using SPSS software version 19 (SPSS Inc.,
Chicago, Ill., USA). Two-tailed p-values ,0.05 were considered
significant.
Results
Table 1 shows data on demographics, referral source, etiology,
presence of cirrhosis and insurance status of the 705 patients who
formed the final study cohort. About half of the subjects were
male, predominantly white and were most frequently referred by
either their primary physician or gastroenterologist. Over 80%
patients had a single etiology for their chronic liver disease. The
most common etiologies were hepatitis C, nonalcoholic fatty liver
disease (NAFLD) or nonalcoholic steatohepatitis (NASH) and
alcohol. Cirrhosis was present in 39.1% patients and approx-
imately one third of cirrhotics had decompendated disease at the
time of evaluation.
Testing for Hepatitis A and B status
HAV antibody was tested in 619/705 (87.7%) patients either
prior to or at the CLD. Of these, 183/619 (29.5%) tested positive
for HAV antibody (Table 2). There were no differences between
patients who did and did not have HAV testing based on
demographics, referral source, distribution and type of etiology,
decompensated cirrhosis and Medicare status.
HBs antigen, HBs antibody and HBc antibody were tested
either before or at the CLD in 90.4% (637/705), 84.5% (596/705)
and 83.8% (591/705) patients, respectively (Table 2). Of the
patients tested, 29.5% were positive for HBs antibody, and 18.8%
were positive for HBc antibody. Patients with etiologies other than
hepatitis C were more likely to be tested for HBs antigen (92.7%
vs. 87.9%, p= 0.03) and those with primary biliary cirrhosis (97%
vs. 83.2%, p= 0.03) were more likely to be tested for HBc
antibody. Otherwise, there were no differences between patients
who did or did not have testing for HBV serology.
Eligibility for vaccination for Hepatitis A and B at CLD
After excluding patients who were HAV antibody positive
(n = 183) or had received HAV vaccination before referral to the
CLD (n= 47; in 25 of these a positive HAV antibody following
vaccination was documented), 411 patients were eligible for HAV
vaccination at the CLD (Figure 1). After excluding patients who
were positive for HBs antibody positive, HBc antibody positive or
received HBV vaccination before referral to the CLD (n= 67), 375
patients were eligible for HBV vaccination at CLD (Figure 1b).
Patients in whom the serological status for HAV and HBV was
unknown (i.e. they did not undergo testing for HAV and/or HBV)
were excluded from consideration of eligibility for vaccination.
Patients who were eligible to receive vaccination for HAV and
HBV were more likely to be white and have NAFLD/NASH or
etiology other than hepatitis C (Tables 3 and 4). While patients
eligible to receive HAV vaccination were more likely to be
younger, have no cirrhosis and have insurance other than
Medicare; those eligible for HBV vaccination were more likely
to be older, have cirrhosis and Medicare insurance (Table 3). The
proportion of patients who were eligible for vaccination for HAV
and HBV were similar across six providers at the CLD (data not
shown).
Vaccination recommendation for Hepatitis A and B at
CLD
In eligible patients, vaccination for HAV and HBV was
recommended at the CLD in only 63% and 59.7%, respectively
(Tables 3 and 4). While hepatitis A vaccination was recommended
more often in eligible patients with no decompensated cirrhosis,
the recommendation for HBV vaccination was not dependent on
demographics, referral source, distribution and type of etiology,
decompensated cirrhosis and Medicare status.
We found significant variability when we analyzed the data by
individual providers (Figure 2). Recommendation for vaccination
in eligible patients ranged from 32.4% to 98.6% for hepatitis A
and 30% to 89.6% for hepatitis B. When we limited the analyses to
patients who had Hepatitis C and Medicare at any point during
the study period, the results for vaccination recommendations
overall and by provider were similar (data not shown).
Barriers to vaccination. Among the 259 patients in whom
HAV vaccination was recommended at the CLD, 177 (68.3%)
underwent vaccination, 3 (1.2%) had partial vaccination (insur-
ance changed in 1, lost in 1 and no specific reason in 1), 38
(14.7%) did not undergo vaccination, and the status of vaccination
was unknown in the remaining 41 (15.8%) patients. The reasons
for not getting vaccination (n= 38) were: no clear reason (24), were
Figure 2. Recommendation for vaccination in eligible patients stratified by liver clinic providers for A) Hepatitis A and B) Hepatitis
B.
doi:10.1371/journal.pone.0071124.g002
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on other medications (hydroxychloroquine and infliximab in one
each), PCP’s office did not have vaccines or did not give it (4), no
prescription given or did not know where to get the vaccine (3), no
insurance coverage (3), lost script (1), and did not have PCP (1).
Discussion
Our study makes several important contributions to the
literature. First, we demonstrate that adherence to HAV and
HBV vaccination guidelines in a specialty hepatology clinic, while
higher than rates reported in community-based practices, is far
from optimal. Second, we show that significant variability in
adherence to vaccination guidelines exists amongst providers
within the same practice. Third, we find that an EHR-based
electronic reminder system did not improve vaccination recom-
mendation rates. Finally, we find that insurance is not a major
impediment to vaccination but lack of adequate counseling and
patient education may be a factor in patient compliance with
vaccination recommendations.
In the current healthcare climate, there is increased focus on
preventive care as a key intervention to provide the most cost-
effective care [20]. We found that just 30% of patients were
immune to HAV and HBV infection prior to referral to the liver
clinic. Our results are similar to a previous study, which reported
that vaccination recommendation rates in primary care clinics
were lower than in specialty clinics [19]. Thus, increasing
awareness of hepatitis vaccination among primary care physicians
is another strategy to potentially improve vaccination rates in
patients with chronic liver disease. Surprisingly, we found that
insurance was a barrier to vaccination in only a small number of
Table 3. Eligibility for Hepatitis A vaccination among 619 new chronic liver disease patients and the proportion where it was
recommended at the liver clinic.
Variable (N)
Eligible for
Vaccination N (%) p-value
Vaccine Recommended
N (%) p-value
Overall (619) 411 (66.3) - 259 (63) -
Age (years) – median (IQR)
Yes (eligible/recommended) 53 (43, 59) ,0.001 53 (42, 60) 0.23
No (not eligible/not recommended) 56 (44, 63) 52 (43, 58)
Gender
Male (327) 209 (63.9) 0.17 139 (66.5) 0.15
Female (292) 202 (69.2) 120 (59.4)
Race
White (532) 371 (69.7) ,0.001 232 (62.5) 0.34
Non White (78) 32 (41) 23 (71.9)
Hepatitis C
Yes (298) 174 (58.4) ,0.001 104 (59.8) 0.26
No (321) 237 (73.8) 155 (65.4)
Alcoholic liver disease
Yes (108) 72 (66.7) 1 43 (59.7) 0.59
No (511) 338 (66.3) 216 (63.7)
NAFLD/NASH*
Yes (172) 129 (75) 0.006 78 (60.5) 0.51
No (447) 282 (63.1) 181 (64.2)
Cirrhosis
Yes (250) 148 (59.2) 0.002 95 (64.2) 0.75
No (369) 263 (71.3) 164 (62.4)
Decompensated cirrhosis
Yes (87) 53 (60.9) 0.18 28 (52.8) 0.049
No (161) 95 (59) 67 (70.5)
Number of etiologies
One (512) 344 (67.2) 0.36 218 (63.4) 0.74
More than one (107) 67 (62.6) 41 (61.2)
Medicare enrolleeˆ
Yes (165) 99 (60.0) 0.043 68 (68.7) 0.19
No (446) 307 (68.8) 187 (60.9)
*NAFLD – nonalcoholic fatty liver disease; NASH – nonalcoholic steatohepatitis.
^Medicare enrollee at anytime during 2008; information missing in 8 patients.
% for eligible patients is based on the number of overall patients.
% for vaccine recommended is based on the number of patients eligible for vaccination.
doi:10.1371/journal.pone.0071124.t003
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patients [21]. We speculate that inadequate explanation or
counseling for the need for vaccination may be one potential
source for noncompliance with vaccination recommendation. It is
likely that this noncompliance may be amenable to approaches
such as patient educational material or involvement of nursing
staff or advanced practitioners in the process.
Recent studies have highlighted variations in quantifiable
outcomes and adherence to well-established guidelines amongst
primary care physicians as well as specialists [22,23,24,25]. Given
that the demographic, etiological, and clinical characteristics of
patients were similar between the providers, the observed
variability in vaccination recommendations cannot be explained
by these patient-specific factors. We did not measure the
characteristics of individual physicians that correlated with
adherence to vaccination guidelines but further research is
warranted to elucidate these variables.
In our clinic, a ‘‘pop-up’’ electronic reminder was activated for
every Medicare patients with a billing diagnosis of HCV infection
and providers could not sign-off on these charts without addressing
specific questions about these patients’ hepatitis vaccination status.
While there was a small financial incentive associated with
complying with the PQRI queries, there was no penalty associated
with noncompliance. We found no difference in vaccine recom-
mendation rates between this cohort of Medicare patients and the
rest of the patient population. Future prospective studies will be
needed to address the question whether such EHR-based
reminder systems can improve compliance with vaccination
guidelines.
Table 4. Eligibility for Hepatitis B vaccination among 637 new chronic liver disease patients and the proportion where it was
recommended at the liver clinic.
Variable (N)
Eligible for
Vaccination N (%) p-value
Vaccine Recommended
N (%) p-value
Overall (637) 375 (58.9) - 224 (59.7) -
Age (years) – median (IQR)
Yes (eligible/recommended) 55 (46, 63) ,0.001 55 (45, 63) 0.56
No (not eligible/not recommended) 52 (40, 58) 54 (46, 61)
Gender
Male (338) 192 (56.8) 0.29 116 (60.4) 0.83
Female (299) 183 (61.2) 108 (59.0)
Race
White (545) 345 (63.3) ,0.001 207 (60.0) 1
Non White (82) 22 (26.8) 13 (59.1)
Hepatitis C
Yes (305) 125 (41.0) ,0.001 67 (53.6) 0.1
No (332) 250 (75.3) 157 (62.8)
Alcoholic liver disease
Yes (111) 74 (66.7) 0.07 38 (51.4) 0.11
No (526) 301 (57.2) 186 (61.8)
NAFLD/NASH*
Yes (175) 123 (70.3) ,0.001 69 (56.1) 0.37
No (462) 252 (54.5) 155 (61.5)
Cirrhosis
Yes (251) 170 (67.7) ,0.001 102 (60.0) 1
No (386) 205 (53.1) 122 (59.5)
Decompensated cirrhosis
Yes (93) 67 (72) 0.33 35 (52.2) 0.11
No (156) 102 (65.4) 67 (65.7)
Number of etiologies
One (532) 310 (58.3) 0.52 190 (61.3) 0.21
More than one (105) 65 (61.9) 34 (52.3)
Medicare enrolleeˆ
Yes (165) 110 (66.7) 0.02 72 (66.5) 0.16
No (463) 261 (56.4) 149 (57.1)
*NAFLD – nonalcoholic fatty liver disease; NASH – nonalcoholic steatohepatitis.
^Medicare enrollee at anytime during 2008; information missing in 9 patients.
% for eligible patients is based on the number of overall patients.
% for vaccine recommended is based on the number of patients eligible for vaccination.
doi:10.1371/journal.pone.0071124.t004
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Several limitations of this study should be noted. First, this was a
retrospective study that was performed at a single center. Second,
we did not record characteristics of individual physicians or
practice pattern differences between physicians and their ad-
vanced practice providers that might explain the individual
variability in vaccination recommendation rates. Third, since
EHR-based reminders were only required during the study period
for Medicare patients with hepatitis C infection, our results on
automated computerized reminders may not be generalizable to
other etiologies and groups of patients.
In summary, we show here that adherence to hepatitis
vaccination guidelines, while higher than reported in communi-
ty-based clinics, was low even in an academic hospital-based
hepatology clinic. Furthermore, there were significant variations
amongst providers, which did not correlate with the number of
patients seen by individual physicians, within the same practice in
adhering to vaccination guidelines in eligible patients. Finally,
most patients who were recommended vaccination but failed to
get them offered no specific reason for their noncompliance,
highlighting the need for better education and counseling of
patients with regard to this important preventive intervention.
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